Antiviral therapy in acute viral hepatitis B: Why and when

被引:1
|
作者
Morelli G. [1 ]
Perrella A. [1 ,2 ]
Sbreglia C. [1 ]
Bellopede P. [1 ]
Riccio V. [1 ]
Perrella O. [1 ]
机构
[1] VII Department of Infectious Diseases and Immunology, D. Cotugno Hospital, Naples
[2] Liver Unit, A. Cardarelli Hospital, Naples
关键词
Lamivudine; Entecavir; Fulminant Hepatitis; Acute Viral Hepatitis; High Serum Bilirubin;
D O I
10.1186/1750-9378-4-2
中图分类号
学科分类号
摘要
Acute viral hepatitis B is cleared in more than 95% of patients, while the remainder ones may develop either chronic HBV infection or, rarely, fulminant hepatitis. Therefore there are elderly patients with severe acute HBV hepatitis caractherized by high serum bilirubin levels >15 mmole/dl, international normalized ratio (INR) with value more than 1.6; these patients are caractherized by a severe outcome of HBV infection. As known, outcome of infection and the pathogenesis of liver diseases are determined by viral and host factors, such as T reg lymphocytes. T regs may be associated with a negative immune response such as an inhibition of gamma- IFN secretion. The impact of viral load on antiviral T cell responses may play a critical role in thaese patients, influencing disease persistence and immune response. Antiviral drugs could be useful in these patients determing a possible down -regulation of T regs.
引用
收藏
相关论文
共 50 条
  • [41] Reduction of liver stiffness by antiviral therapy in chronic hepatitis B
    Osakabe, Keisuke
    Ichino, Naohiro
    Nishikawa, Toru
    Sugiyama, Hiroko
    Kato, Miho
    Kitahara, Shiho
    Hashimoto, Senju
    Kawabe, Naoto
    Harata, Masao
    Nitta, Yoshifumi
    Murao, Michihito
    Nakano, Takuji
    Shimazaki, Hiroaki
    Arima, Yuko
    Suzuki, Koji
    Yoshioka, Kentaro
    JOURNAL OF GASTROENTEROLOGY, 2011, 46 (11) : 1324 - 1334
  • [42] Hepatitis B virus escape mutants induced by antiviral therapy
    Sheldon, Julie
    Soriano, Vincent
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 61 (04) : 766 - 768
  • [44] Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis
    Ju, Young-Cheol
    Jun, Dae-Won
    Choi, Jun
    Saeed, Waciar Khalid
    Lee, Hyo-Young
    Oh, Hyun-Woo
    WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (40) : 4606 - 4614
  • [45] Antiviral therapy for hepatitis B virus associated hepatic failure
    Yu-Ming Wang and Ying-Zi Tang Institute for Infectious Diseases of PLA
    Hepatobiliary & Pancreatic Diseases International, 2009, 8 (01) : 17 - 24
  • [46] Entecavir and lamivudine therapy for severe acute chronic hepatitis B
    Liu, Changhong
    Ye, Jing
    Jia, Hongyu
    Zhang, Meijuan
    Han, Hongfeng
    Chen, Fengzhe
    Chen, Congkang
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2013, 5 (02) : 545 - 548
  • [47] Management of Antiviral Resistance in Chronic Hepatitis B
    Lim, Young-Suk
    GUT AND LIVER, 2017, 11 (02) : 189 - 195
  • [48] Current antiviral therapies for chronic hepatitis B
    Inada, Mari
    Yokosuka, Osamu
    HEPATOLOGY RESEARCH, 2008, 38 (06) : 535 - 542
  • [49] Antiviral options for the treatment of chronic hepatitis B
    Osborn, Melissa K.
    Lok, Anna S. F.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 57 (06) : 1030 - 1034
  • [50] Is Combination Antiviral Therapy Mandatory for Maintenance Therapy in Fully Suppressed Multidrug-Resistant Hepatitis B Patients?
    Chung, Sung Won
    Chang, Young
    Lee, Hyo Young
    Cho, Eun Ju
    Lee, Jeong-Hoon
    Yu, Su Jong
    Yoon, Jung-Hwan
    Kim, Yoon Jun
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2018, 2018